A recent report has suggested that PARP inhibitor Olaparib treatment induces changes in the tumor microenvironment of BRCA1-mutated TNBC cells and induces CD8+ T cell infiltration and activation in vivo [94]. The gene discussed is BRCA1; the disease is neoplasm.